혈당 모니터링 기기 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 접속성별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Blood Glucose Monitoring Devices Market Summary

The global blood glucose monitoring devices market size was estimated at USD 15.53 billion in 2025 and is projected to reach USD 30.18 billion by 2033, growing at a CAGR of 8.8% from 2026 to 2033. The market is primarily influenced by the growing prevalence of diabetes and growing elderly population susceptible to conditions such as diabetes.

In addition, market growth is driven by rising awareness of preventive measures for diabetes and the introduction of new products. Diabetes, a widespread and increasing global concern, is characterized by the pancreas' inability to efficiently produce insulin, leading to elevated blood glucose levels. Moreover, the technology associated with blood glucose monitoring not only aids immediate intervention but also serves as a valuable tool for patient education on diabetes and its effective management.

The rising global prevalence of diabetes is anticipated to drive strong market demand during the forecast period. According to the Institute for Health Metrics and Evaluation (June 2023), over 500 million people worldwide currently live with diabetes, impacting individuals across all demographics. With a global prevalence of 6.1%, diabetes ranks among the top 10 causes of death and disability. North Africa and the Middle East lead with a 9.3% prevalence, which is expected to increase to 16.8% by 2050. In Latin America and the Caribbean, the prevalence is projected to rise to 11.3%.

In addition, market growth is driven by rising awareness of preventive measures for diabetes and the introduction of new products. Diabetes, a widespread and growing global concern, is characterized by the pancreas' inability to efficiently produce insulin, leading to elevated blood glucose levels. According to the International Diabetes Federation, approximately 537 million individuals were diagnosed with diabetes in 2021, and projections indicate an anticipated rise to 643 million by 2030 and 783 million by 2045.

Blood glucose monitoring (BGM) devices play a crucial role in supporting individuals with diabetes in numerous ways. Initially, they empower both patients and healthcare professionals to identify elevated or reduced blood glucose levels, enabling timely adjustments to treatment plans. This capability serves as a protective measure by promptly confirming acute hypoglycemia or hyperglycemia, ensuring the well-being of patients. In addition, these devices enhance self-care practices, offering individuals greater control over their diabetes management. Moreover, the technology associated with blood glucose monitoring not only aids in immediate intervention but also serves as a valuable tool for patient education on diabetes and its effective management.

The prevalence of diabetes tends to increase with age, and older adults are more susceptible to developing diabetes or experiencing complications related to the disease. As the geriatric population increases, so does the pool of individuals at risk of diabetes, creating a greater demand for blood glucose monitoring devices. For instance, based on the National Diabetes Statistics Report, in 2021, in the U.S. 27.2 million adults aged 65 years or older had prediabetes. Studies have shown that real-time continuous glucose monitoring (CGM) is effective and safe in adults aged 65 years and older with type 2 diabetes. Participants aged 65 years and above showed a significant improvement in their hemoglobin A1c (HbA1c) levels, which indicates better control of blood glucose levels when using CGM compared to blood glucose monitoring (BGM). These results underscore the potential value of CGM devices as a beneficial tool for effectively managing diabetes in the elderly population.

The COVID-19 pandemic has significantly impacted the market. The pandemic highlighted healthcare disparities and technological importance, including BGM devices. Regulatory changes, such as relaxed requirements for obtaining continuous glucose monitoring (CGM), have increased access to these devices, particularly benefiting those who can benefit from the technology. Furthermore, the use of real-time continuous glucose monitoring (rtCGM) was observed during lockdowns for improved glycemic control, reducing the time in range & glucose variability, thereby significantly boosting the overall market growth.

Global Blood Glucose Monitoring Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood glucose monitoring devices market report on the basis of product, connectivity, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Self-Monitoring Devices
  • Blood Glucose Meters
  • Traditional BGMs
  • Smart BGMs
  • Testing Strips
  • Lancets
• Continuous Glucose Monitoring (CGM) Devices
  • Sensors
  • Transmitter and Receiver
  • Insulin Pumps
  • Traditional Insulin Pumps
  • Smart Insulin Pumps
• Connectivity Outlook (Revenue, USD Million, 2021 - 2033)
• Bluetooth-Enabled Devices
• Wi-Fi-Enabled Devices
• Near Field Communication (NFC) Devices
• USB Connectivity Devices
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Home Care
• Diagnostic Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
  • Mexico
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Connectivity Segment
  • 1.2.3. End-use Segment
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Regional Scope
• 1.4. Estimates and Forecast Timeline
• 1.5. Objectives
  • 1.5.1. Objective - 1
  • 1.5.2. Objective - 2
• 1.6. Research Methodology
• 1.7. Information Procurement
  • 1.7.1. Purchased Database
  • 1.7.2. GVR's Internal Database
  • 1.7.3. Secondary Sources
  • 1.7.4. Primary Research
• 1.8. Information or Data Analysis
  • 1.8.1. Data Analysis Models
• 1.9. Market Formulation & Validation
• 1.10. Model Details
  • 1.10.1. Commodity Flow Analysis
• 1.11. List of Primary Sources
• 1.12. List of Abbreviations

Chapter 2. Blood Glucose Monitoring Devices Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Products, Connectivity, and End Use Snapshots
• 2.3. Competitive Landscape Snapshot

Chapter 3. Blood Glucose Monitoring Devices Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising geriatric population worldwide
  • 3.4.2. Increasing number of diabetes patients
  • 3.4.3. Increasing awareness about diabetes preventive care
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of devices
• 3.6. Blood Glucose Monitoring Devices Market Analysis Tools
  • 3.6.1. Industry Analysis - Porter's
    • 3.6.1.1. Supplier Power
    • 3.6.1.2. Buyer Power
    • 3.6.1.3. Substitution Threat
    • 3.6.1.4. Threat Of New Entrant
    • 3.6.1.5. Competitive Rivalry
  • 3.6.2. PESTLE Analysis
    • 3.6.2.1. Political Landscape
    • 3.6.2.2. Technological Landscape
    • 3.6.2.3. Economic Landscape
  • 3.6.3. Pricing Analysis

Chapter 4. Blood Glucose Monitoring Devices: Product Estimates & Trend Analysis

• 4.1. Global Blood Glucose Monitoring Market: Product Segment Dashboard
• 4.2. Global Blood Glucose Monitoring Devices Market by Product Outlook
• 4.3. Global Blood Glucose Monitoring Devices Market Size & Trend Analysis, by Product, 2021 - 2033 (USD Million)
• 4.4. Self-Monitoring Devices
  • 4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Blood Glucose Meter
    • 4.4.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.4.2.2. Traditional BGMs
      • 4.4.2.2.1 Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.4.2.3. Smart BGMs
      • 4.4.2.3.1 Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.3. Testing Strips
    • 4.4.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.4. Lancets
    • 4.4.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 4.5. Continuous Blood Glucose Monitoring Devices
  • 4.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.2. Sensors
    • 4.5.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.3. Transmitter & Receiver
    • 4.5.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.4. Insulin Pumps
    • 4.5.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.5.4.2. Traditional Insulin Pumps
      • 4.5.4.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 4.5.4.3. Smart Insulin Pumps
      • 4.5.4.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 5. Blood Glucose Monitoring Devices: Connectivity Estimates & Trend Analysis

• 5.1. Global Blood Glucose Monitoring Market: Connectivity Segment Dashboard
• 5.2. Global Blood Glucose Monitoring Market: Connectivity Movement Analysis
• 5.3. Global Blood Glucose Monitoring Market Size & Trend Analysis, by Connectivity, 2021 - 2033 (USD Million)
• 5.4. Bluetooth-Enabled Devices
  • 5.4.1 Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 5.5 Wi-Fi-Enabled Devices
  • 5.5.1 Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 5.6 Near Field Communication (NFC) Devices
  • 5.6.1 Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 5.7 USB Connectivity Devices
  • 5.7.1 Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 6. Blood Glucose Monitoring Devices: End Use Estimates & Trend Analysis

• 6.1. Global Blood Glucose Monitoring Market: End Use Segment Dashboard
• 6.2. Global Blood Glucose Monitoring Market: End Use Movement Analysis
• 6.3. Global Blood Glucose Monitoring Market Size & Trend Analysis, by End Use, 2021 - 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 6.5. Homecare
  • 6.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 6.6. Diagnostics Centers
  • 6.6.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Regional Market Dashboard
• 7.2. Global Regional Market Snapshot
• 7.3. Marker Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key Country Dynamics
    • 7.4.1.2. Competitive Scenario
    • 7.4.1.3. Regulatory Framework
    • 7.4.1.4. U.S. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Canada Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Competitive Scenario
    • 7.5.1.3. Regulatory Framework
    • 7.5.1.4. UK Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Germany Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.5.3. Spain
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Spain Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.5.6. Denmark
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Denmark Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Sweden Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Norway Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Competitive Scenario
    • 7.6.1.3. Regulatory Framework
    • 7.6.1.4. Japan Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. China Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. India Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.6.4. South Korea
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. South Korea Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.6.5. Thailand
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Thailand Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Australia Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Competitive Scenario
    • 7.7.1.3. Regulatory Framework
    • 7.7.1.4. Brazil Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.7.2. Mexico
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Mexico Blood Glucose Monitoring Devices Market, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Competitive Scenario
    • 7.8.1.3. Regulatory Framework
    • 7.8.1.4. South Africa Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. UAE Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Kuwait Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company /Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List Of Key Distributors and Channel Partners
  • 8.3.2. Key Customers
  • 8.3.3. Key Company Market Share Analysis, 2025
    • 8.3.3.1. Abbott Laboratories
      • 8.3.3.1.1. Company overview
      • 8.3.3.1.2. Financial performance
      • 8.3.3.1.3. Product benchmarking
      • 8.3.3.1.4. Strategic initiatives
    • 8.3.3.2. Medtronic plc
      • 8.3.3.2.1. Company overview
      • 8.3.3.2.2. Financial performance
      • 8.3.3.2.3. Product benchmarking
      • 8.3.3.2.4. Strategic initiatives
    • 8.3.3.3. F. Hoffmann-La Roche Ltd
      • 8.3.3.3.1. Company overview
      • 8.3.3.3.2. Financial performance
      • 8.3.3.3.3. Product benchmarking
      • 8.3.3.3.4. Strategic initiatives
    • 8.3.3.4. Dexcom, Inc.
      • 8.3.3.4.1. Company overview
      • 8.3.3.4.2. Financial performance
      • 8.3.3.4.3. Product benchmarking
      • 8.3.3.4.4. Strategic initiatives
    • 8.3.3.5. Sanofi
      • 8.3.3.5.1. Company overview
      • 8.3.3.5.2. Financial performance
      • 8.3.3.5.3. Product benchmarking
      • 8.3.3.5.4. Strategic initiatives
    • 8.3.3.6. Novo Nordisk
      • 8.3.3.6.1. Company overview
      • 8.3.3.6.2. Financial performance
      • 8.3.3.6.3. Product benchmarking
      • 8.3.3.6.4. Strategic initiatives
    • 8.3.3.7. Insulet Corporation
      • 8.3.3.7.1. Company overview
      • 8.3.3.7.2. Financial performance
      • 8.3.3.7.3. Product benchmarking
      • 8.3.3.7.4. Strategic initiatives
    • 8.3.3.8. Ypsomed Holdings
      • 8.3.3.8.1. Company overview
      • 8.3.3.8.2. Financial performance
      • 8.3.3.8.3. Product benchmarking
      • 8.3.3.8.4. Strategic initiatives
    • 8.3.3.9. Glysens Incorporated
      • 8.3.3.9.1. Company overview
      • 8.3.3.9.2. Financial performance
      • 8.3.3.9.3. Product benchmarking
      • 8.3.3.9.4. Strategic initiatives
    • 8.3.3.10. Senseonics Holdings, Inc.
      • 8.3.3.10.1. Company overview
      • 8.3.3.10.2. Financial performance
      • 8.3.3.10.3. Product benchmarking
      • 8.3.3.10.4. Strategic initiatives
    • 8.3.3.11. GlucoRx Limited
      • 8.3.3.11.1. Company overview
      • 8.3.3.11.2. Financial performance
      • 8.3.3.11.3. Product benchmarking
      • 8.3.3.11.4. Strategic initiatives
    • 8.3.3.12. Zhejiang POCTech Co., Ltd
      • 8.3.3.12.1. Company overview
      • 8.3.3.12.2. Financial performance
      • 8.3.3.12.3. Product benchmarking
      • 8.3.3.12.4. Strategic initiatives
    • 8.3.3.13. i-SENS, Inc.
      • 8.3.3.13.1. Company overview
      • 8.3.3.13.2. Financial performance
      • 8.3.3.13.3. Product benchmarking
      • 8.3.3.13.4. Strategic initiatives
    • 8.3.3.14. Nemaura Medical Inc.
      • 8.3.3.14.1. Company overview
      • 8.3.3.14.2. Financial performance
      • 8.3.3.14.3. Product benchmarking
      • 8.3.3.14.4. Strategic initiatives
    • 8.3.3.15. Sinocare, Inc.
      • 8.3.3.15.1. Company overview
      • 8.3.3.15.2. Financial performance
      • 8.3.3.15.3. Product benchmarking
      • 8.3.3.15.4. Strategic initiatives
    • 8.3.3.16. Bionime
      • 8.3.3.16.1. Company overview
      • 8.3.3.16.2. Financial performance
      • 8.3.3.16.3. Product benchmarking
      • 8.3.3.16.4. Strategic initiatives
    • 8.3.3.17. AgaMatrix
      • 8.3.3.17.1. Company overview
      • 8.3.3.17.2. Financial performance
      • 8.3.3.17.3. Product benchmarking
      • 8.3.3.17.4. Strategic initiatives